Program
pitavastatin
Also written as “Pitavastatin”, “Pitavastatin (NK-104)” and “NK-104-CR”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Renal Insufficiency · Dyslipidemias · Diabetes Mellitus, Type 2, led by 5 companies.
Drug pagePitavastatin: every studyMany companies study it; this page follows only the 29 they lead. All 75 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kowaits history only | 180 open or running | phase 4since Dec 18, 2009 | Nov 4, 2005 | none ahead |
| JW Pharmaceuticalits history only | 80 open or running | phase 4since Mar 18, 2008 | Mar 18, 2008 | none ahead |
| Merckits history only | 10 open or running | phase 1since Oct 12, 2017 | Oct 12, 2017 | none ahead |
| Orient Pharmaits history only | 10 open or running | phase 3since Oct 16, 2012 | Oct 16, 2012 | none ahead |
| Tai Tien Pharmaceuticalsits history only | 10 open or running | phase 3since Jun 29, 2011 | Jun 29, 2011 | none ahead |
Also a collaborator on its studies: Orient Europharma, Kowa Pharmaceuticals America and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Nov 4, 2005.
- Jan 25, 2010Phase 4 study in Healthy VolunteersKowa · NCT01057433 · 24 enrolled · United States
- Jul 19, 2010Phase 4 study in HypercholesterolemiaJW Pharmaceutical · NCT01166633 · 200 enrolled
- Dec 7, 2010Phase 4 study in Primary DyslipidemiaKowa · NCT01256476 · 328 enrolled · United States
- Feb 18, 2011Phase 4 study in DyslipidemiasKowa · NCT01301066 · 252 enrolled · United States
- Jun 29, 2011Tai Tien Pharmaceuticals’ first study: phase 3 study in HyperlipidemiasNew to Tai Tien PharmaceuticalsTai Tien Pharmaceuticals · NCT01386853 · 200 enrolled · Taiwan
- Jul 26, 2011Phase 1 study in HyperlipidemiasJW Pharmaceutical · NCT01406431 · 48 enrolled · Korea, Republic of
- Aug 22, 20112 phase 4 studies in HealthyKowa · NCT01422382, NCT01422369
- May 2, 2012Phase 1 study in Metabolic SyndromeKowa · NCT01595828 · 14 enrolled · United Kingdom
- Oct 16, 2012Orient Pharma’s first study: phase 3 study in HypercholesterolemiaNew to Orient PharmaOrient Pharma · NCT01710007 · 202 enrolled · Taiwan
- Feb 4, 2014Phase 4 study in HyperlipidemiasJW Pharmaceutical · NCT02056847 · 313 enrolled · Korea, Republic of
- Jan 28, 2016Phase 3 study in HyperlipidemiasKowa · NCT02670434 · United States
- Jun 10, 2016Phase 3 study in HyperlipidemiasKowa · NCT02799758 · United States
- Oct 12, 2017Merck’s first study: phase 1 study in Renal InsufficiencyNew to MerckMerck · NCT03311841 · 32 enrolled · United States
- Oct 6, 2020Phase 3 study in Primary HypercholesterolemiaJW Pharmaceutical · NCT04584736 · 283 enrolled · Korea, Republic of
TargetBeta
“HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| Simvastatinrule | Organon | phase 4 | 100 |
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04584736Primary Hypercholesterolemia · Korea, Republic of | 3 | Completed | JW Pharmaceutical | Jul 16, 2020 | 283 |
| NCT03311841Renal Insufficiency · United States | 1 | Completed | Merck | Aug 2, 2018 | 32 |
| NCT02799758Hyperlipidemias · United States | 3 | Withdrawn | Kowa | Jul 2017 | 0 |
| NCT02670434Hyperlipidemias · United States | 3 | Withdrawn | Kowa | Jul 2017 | 0 |
| NCT02056847Hyperlipidemias · Korea, Republic of | 4 | Completed | JW Pharmaceutical | May 2017 | 313 |
| NCT01710007Hypercholesterolemia · Taiwan | 3 | Completed | Orient Pharma | Sep 2012 | 202 |
| NCT01595828Metabolic Syndrome · United Kingdom | 1 | Completed | Kowa | Jun 2012 | 14 |
| NCT01422382Healthy · United States | 4 | Completed | Kowa | Jun 2011 | 28 |
| NCT01422369Healthy · United States | 4 | Completed | Kowa | Jun 2011 | 28 |
| NCT01406431Hyperlipidemias · Korea, Republic of | 1 | Completed | JW Pharmaceutical | Aug 2011 | 48 |
| NCT01386853Hyperlipidemias · Taiwan | 3 | UNKNOWN | Tai Tien Pharmaceuticals | Mar 2012 | 200 |
| NCT01301066Dyslipidemias · United States | 4 | Completed | Kowa | Mar 2013 | 252 |
| NCT01256476Primary Dyslipidemia · United States | 4 | Completed | Kowa | Jun 2011 | 328 |
| NCT01166633Hypercholesterolemia | 4 | Completed | JW Pharmaceutical | Nov 2010 | 200 |
| NCT01057433Healthy Volunteers · United States | 4 | Completed | Kowa | Dec 2010 | 24 |
| NCT01043094Renal Insufficiency · United States | 4 | Completed | Kowa | Apr 2010 | 16 |
| NCT00889226Hypercholesterolemia With Type2DM | 4 | Completed | JW Pharmaceutical | May 2009 | 161 |
| NCT00786734Angina, Stable · Korea, Republic of | 4 | Withdrawn | JW Pharmaceutical | May 2009 | 0 |
| NCT00701285Heart Failure · Korea, Republic of | 4 | Completed | JW Pharmaceutical | May 2013 | 70 |
| NCT00640276Hypercholesterolemia · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Feb 2011 | 187 |
| NCT00344370Diabetes Mellitus, Type 2 · Denmark, Germany, India and more | 3 | Completed | Kowa | Apr 2008 | 214 |
| NCT00344175Hypercholesterolemia · Denmark, Netherlands, Spain and more | 3 | Completed | Kowa | Aug 2007 | 178 |
| NCT00330876Hypercholesterolemia · Denmark, Germany, Israel and more | 3 | Completed | Kowa | Dec 2007 | 545 |
| NCT00325780Hypercholesterolemia · Denmark, Finland, Germany and more | 3 | Completed | Kowa | Nov 2007 | 1,355 |
| NCT00309751Diabetes Mellitus, Type 2 · Denmark, Germany, India and more | 3 | Completed | Kowa | Jun 2007 | 418 |
| NCT00309738Hypercholesterolemia · Denmark, Netherlands, Spain and more | 3 | Completed | Kowa | Oct 2006 | 355 |
| NCT00257686Hypercholesterolemia · Denmark, Germany, Israel and more | 3 | Completed | Kowa | May 2006 | 962 |
| NCT00309777Hypercholesterolemia · Finland, Italy, Norway and more | 3 | Completed | Kowa | Oct 2006 | 857 |
| NCT00249249Dyslipidemias · Denmark, Finland, Germany and more | 3 | Completed | Kowa | 830 |
How it is read
Names in the registry
- “Pitavastatin”, 18 entries
- “pitavastatin”, 8 entries
- “Pitavastatin (NK-104)”, 3 entries
- “NK-104-CR”, 2 entries
- “pitavastatin single dose combined with ceftobiprole”, 1 entry
Conditions, from the studies’ own filings
- Hypercholesterolemia, 13 studies
- Hyperlipidemias, 5 studies
- Renal Insufficiency, 2 studies
- Dyslipidemias, 2 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.